RxDoctor Payments Data

Nicolas Raio, MD

Cardiovascular Disease · Garden City, NYNPI 1497747240

Payments from drug & device makers

$1,514in general payments, 2019–2025

Across 35 payments — averaging $43.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$301
  • Novartis$264
  • Johnson & Johnson$248
  • Impulse Dynamics (USA) Inc.$163
  • Abbott$150
  • Vivaquant Inc, Dba Rhythm Express$130
  • plus $260 from 3 others

What the payments were for

  • Food & beverage$1,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$301
Novartis21$264
Johnson & Johnson2$248
Impulse Dynamics (USA) Inc.1$163
Abbott1$150
Vivaquant Inc, Dba Rhythm Express1$130
Phathom Pharmaceuticals, Inc.1$125
Medtronic(2 entities)2$118
Amgen1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,514 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$398,240
Medicare patients
865
Services billed
4,187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis45$1,557,225
EntrestoSacubitril/Valsartan219$272,182
EliquisApixaban216$263,260
FarxigaDapagliflozin Propanediol97$112,849
XareltoRivaroxaban91$110,793
JardianceEmpagliflozin77$103,018
Repatha SureclickEvolocumab48$51,644
BrilintaTicagrelor24$23,279
Praluent PenAlirocumab16$21,305
NexletolBempedoic Acid13$15,437
NexlizetBempedoic Acid/Ezetimibe14$14,626
Eplerenone148$10,829
Metoprolol Succinate472$8,359
Rosuvastatin Calcium446$6,154
Ranolazine ErRanolazine31$5,273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$264$272,182219 claims
Johnson & JohnsonXarelto$248$110,79391 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →